Elanco Animal Health Incorporated

NYSE-ELAN

Operating Activities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Net Income	78	356	-18	-1,237	6	-119
Net Income
Depreciation & Amortization	330	334	328	344	350	335
Depreciation and Amortization
Share-Based Compensation Expense	35	30	25	25	21	28
Stock-Based Compensation Expense
Other Adjustments	-25	-685	22	1,050	12	36
Goodwill Impairment
Deferred Income Taxes
Asset Impairment and Write-Down Charges
Loss on Sale of Assets
Inventory Fair Value Step-Up Amortization
Gain on Divestiture
Gain on Divestitures
Loss on Extinguishment of Debt
Proceeds from Interest Rate Swap Settlements
Sold Portion of Royalty Revenue
Interest on Liability for Sale of Future Revenue
Other Non-Cash Operating Activities, Net
Changes in Trade Receivables	—	12	—	-40	—	14
Change in Receivables
Changes in Inventories	—	44	—	-160	—	-269
Inventories
Changes in Accounts Payable	—	82	—	-94	—	-98
Accounts Payable and Other Liabilities
Changes in Other Operating Activities	-185	166	-155	467	-473	275
Changes in Operating Assets and Liabilities, Net of Acquisitions and Divestitures
Other Assets
Other Changes in Operating Assets and Liabilities
Cash from Operating Activities	233	339	202	355	-84	202
Net Cash Provided by Operating Activities

Investing Activities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Capital Expenditure	-122	-89	-58	-74	-66	-113
Purchases of Property and Equipment
Net Purchases of Property and Equipment and Software
Purchases of Intangible Assets	—	-14	—	—	-14	-12
Purchases of Intangible Assets
Purchases of Software
Payments for Business Acquisitions	—	-41	—	-3	-16	—
Cash Paid for Acquisitions, Net of Cash Acquired
Proceeds from Business Divestments	9	1,294	66	—	—	13
Divestiture Proceeds
Proceeds from Aqua Business Divestiture
Proceeds from Divestitures
Other Investing Activities	-1	4	-4	6	-2	-1
Proceeds from Settlement of Net Investment Hedges
Other Investing Activities, Net
Cash from Investing Activities	-114	1,154	4	-71	-98	-113
Net Cash (Used For) Provided by Investing Activities

Financing Activities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Issuance of Short-Term Debt	250	—	220	350	250	—
Proceeds from Revolving Credit Facility
Proceeds from Securitization Facility
Repayments of Short-Term Debt	-250	-145	-300	-275	—	-75
Repayments of Revolving Credit Facility
Repayments of Securitization Facility
Net Issuance / (Repayments) of Short-Term Debt	—	-145	-80	75	250	-75
Issuance of Long-Term Debt	—	350	—	—	—	—
Proceeds from Issuance of Long-Term Debt
Repayments of Long-Term Debt	-374	-1,575	-25	-370	-32	-149
Repayments of Long-Term Borrowings
Net Issuance / (Repayments) of Long-Term Debt	-374	-1,225	-25	-370	-32	-149
Issuance of Common Shares	—	—	—	—	—	—
Proceeds from Issuance of Common Stock and Tangible Equity Units
Net Issuance / (Repurchases) of Common Shares	—	—	—	—	—	—
Other Financing Activities	270	-2	-15	-1	-5	-30
Debt Issuance Costs
Consideration Paid to Lilly in Connection with the Separation
Other Net Transactions with Lilly
Funding Related to Construction of Corporate Headquarters
Proceeds from Sale of Future Revenue, Net of Transaction Costs
Other Financing Activities, Net
Cash from Financing Activities	-104	-1,372	-120	-296	213	-253
Net Cash Used for Financing Activities